Document Detail

Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts.
MedLine Citation:
PMID:  21741479     Owner:  NLM     Status:  MEDLINE    
Ranolazine is a clinically approved drug for treating cardiac ventricular dysrhythmias and angina. Its mechanism(s) of protection is not clearly understood but evidence points to blocking the late Na+ current that arises during ischemia, blocking mitochondrial complex I activity, or modulating mitochondrial metabolism. Here we tested the effect of ranolazine treatment before ischemia at the mitochondrial level in intact isolated hearts and in mitochondria isolated from hearts at different times of reperfusion. Left ventricular (LV) pressure (LVP), coronary flow (CF), and O2 metabolism were measured in guinea pig isolated hearts perfused with Krebs-Ringer's solution; mitochondrial (m) superoxide (O2·-), Ca2+, NADH/FAD (redox state), and cytosolic (c) Ca2+ were assessed on-line in the LV free wall by fluorescence spectrophotometry. Ranolazine (5 μM), infused for 1 min just before 30 min of global ischemia, itself did not change O2·-, cCa2+, mCa2+ or redox state. During late ischemia and reperfusion (IR) O2·- emission and m[Ca2+] increased less in the ranolazine group vs. the control group. Ranolazine decreased c[Ca2+] only during ischemia while NADH and FAD were not different during IR in the ranolazine vs. control groups. Throughout reperfusion LVP and CF were higher, and ventricular fibrillation was less frequent. Infarct size was smaller in the ranolazine group than in the control group. Mitochondria isolated from ranolazine-treated hearts had mild resistance to permeability transition pore (mPTP) opening and less cytochrome c release than control hearts. Ranolazine may provide functional protection of the heart during IR injury by reducing cCa2+ and mCa2+ loading secondary to its effect to block the late Na+ current. Subsequently it indirectly reduces O2·- emission, preserves bioenergetics, delays mPTP opening, and restricts loss of cytochrome c, thereby reducing necrosis and apoptosis.
Mohammed Aldakkak; Amadou K S Camara; James S Heisner; Meiying Yang; David F Stowe
Related Documents :
1389709 - Spontaneously acquired fistula from the right coronary artery to the right ventricular ...
17117759 - Non-invasive imaging of a giant right coronary artery due to a coronary fistula.
25253629 - Collateralization and ischemia in hemodynamic cerebrovascular insufficiency.
19685519 - Long-term prognosis of non-interventionally followed patients with isolated myocardial ...
7300449 - Coronary artery spasm and myocardial infarction in the absence of angiographically demo...
19136759 - Milrinone infusion: a therapeutic option in coronary vasospasm after primary percutaneo...
17303269 - Noncompaction and endocarditis in suspected mitochondrial disorder.
12734529 - Transient myocardial ischemia is an independent predictor of adverse in-hospital outcom...
23456409 - Acute coronary syndromes: advances in antithrombotics.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2011-06-29
Journal Detail:
Title:  Pharmacological research : the official journal of the Italian Pharmacological Society     Volume:  64     ISSN:  1096-1186     ISO Abbreviation:  Pharmacol. Res.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-19     Completed Date:  2012-01-19     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  8907422     Medline TA:  Pharmacol Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  381-92     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / pharmacology,  therapeutic use*
Calcium / metabolism*
Enzyme Inhibitors / pharmacology,  therapeutic use*
Guinea Pigs
Heart / drug effects
Membrane Potential, Mitochondrial / drug effects
Mitochondria, Heart / drug effects*,  metabolism
Myocardial Reperfusion Injury / metabolism,  prevention & control*
Oxidative Stress / drug effects*
Piperazines / pharmacology,  therapeutic use*
Grant Support
Reg. No./Substance:
0/Acetanilides; 0/Enzyme Inhibitors; 0/Piperazines; 110445-25-5/ranolazine; SY7Q814VUP/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Twice switched at birth: Cell cycle-independent roles of the "neuron-specific" cyclin-dependent kina...
Next Document:  The unusual extended C-terminal helix of the peroxisomal ?/?-hydrolase Lpx1 is involved in dimer con...